Understanding the Use of Atypical Antipsychotic Treatment for Major Depressive Disorder: An International Cross-Sectional Survey of Health Care Providers

Read full text Summarise with VIRAT
Authors: Dusica Hadzi Boskovic, Shivani Kapadia, Ferhat Can Ardic, Debra F. Eisenberg, Joe Hickey, Olivia Rogerson, Fiona Glen
Cited by: 0
References: 50

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PURPOSE: The aim of this study was to describe pharmacological prescribing patterns for major depressive disorder (MDD), particularly regarding the use of atypical antipsychotics (AAPs) for the treatment of MDD, and the underlying factors that may influence decision-making. METHODS: An electronic cross-sectional survey with 210 health care professionals (HCPs) involved in the treatment of MDD in 4 countries [United States (57), Canada (53), Brazil (39), Japan (61)] was conducted in May 2024 to July 2024. RESULTS: Of the total HCPs, 62.9% (n = 132) were psychiatrists, 31.9% (n = 67) primary care physicians or general practitioners, and 5.2% (n = 11) nurse practitioners or physician assistants. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed first-line antidepressants across all countries surveyed. Regardless of disease severity, the first step for patients with inadequate response to the first antidepressant treatment was reported to be switching to another antidepressant (mild MDD: 66.7%, moderate MDD: 56.2%, severe MDD: 41.0%). Overall, SSRIs were the most common treatment class, typically augmented with AAPs, followed by serotonin-norepinephrine reuptake inhibitors. HCPs across the countries surveyed increasingly utilized augmentation with AAPs as the severity of MDD increased, with the severity of the current depressive episode and the number of prior antidepressants being the most important patient and treatment factors, respectively, in this decision. In addition, symptom domains, particularly underactive noradrenergic/norepinephrinergic activity and anxiety, were deemed crucial by HCPs in later treatment lines. CONCLUSIONS: The study highlighted complex treatment paradigms in MDD and the need for alternative therapeutic strategies and more tailored options that specifically target receptor pharmacology.

Fields of Study & Subjects

Treatment of Major Depression Mental Health Treatment and Access Electroconvulsive Therapy Studies

Publication details

Journal / source
Journal of Clinical Psychopharmacology
Volume
46
Issue
3
Pages
269–279
Publication date
26 March 2026
Language
EN